DUPIXENT is a targeted therapy towards IL-4 and IL-13 signalling, key drivers of persistent underlying Type 2 inflammation1,6
aged ≥ 12 years with moderate-to-severe AD and children 6–11 years with severe AD, have been prescribed DUPIXENT worldwide as of July 20212
Real-world experience (RWE) has outcome data similar to that from Phase 3 clinical trials3–5
Learn about the different reimbursement criteria for DUPIXENT for people ≥ 12 years with moderate-to-severe AD and children 6–11 years with severe AD
Explore the efficacy data in children aged 6-11 years old with severe AD
Learn more about the safety profile of DUPIXENT in children aged 6–11 years old with severe AD
AD, atopic dermatitis; IL, interleukin.
References
